101. Role of the DNA damage response in prostate cancer formation, progression and treatment
- Author
-
Julie Nonnekens, Luca Incrocci, Wenhao Zhang, Dik C. van Gent, Wytske M. van Weerden, Molecular Genetics, Radiotherapy, Urology, and Radiology & Nuclear Medicine
- Subjects
Male ,0301 basic medicine ,Cancer Research ,DNA Repair ,Cancer therapy ,DNA repair ,DNA damage ,Urology ,medicine.medical_treatment ,Review Article ,Disease ,Gene mutation ,urologic and male genital diseases ,Bioinformatics ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Biomarkers, Tumor ,medicine ,Humans ,Genetic Predisposition to Disease ,Molecular Targeted Therapy ,Cancer genetics ,Germ-Line Mutation ,business.industry ,Disease Management ,Genetic Variation ,Prostatic Neoplasms ,Correction ,medicine.disease ,Combined Modality Therapy ,Radiation therapy ,Androgen receptor ,Crosstalk (biology) ,Treatment Outcome ,030104 developmental biology ,Oncology ,Receptors, Androgen ,030220 oncology & carcinogenesis ,Mutation ,Disease Progression ,Disease Susceptibility ,business ,DNA Damage ,Signal Transduction - Abstract
Background Clinical and preclinical studies have revealed that alterations in DNA damage response (DDR) pathways may play an important role in prostate cancer (PCa) etiology and progression. These alterations can influence PCa responses to radiotherapy and anti-androgen treatment. The identification of DNA repair gene aberrations in PCa has driven the interest for further evaluation whether these genetic changes may serve as biomarkers for patient stratification. Methods In this review, we summarize the current knowledge on DDR alterations in PCa, their potential impact on clinical interventions and prospects for improved management of PCa. We particularly focus on the influence of DDR gene mutations on PCa initiation and progression and describe the underlying mechanisms. Results and Conclusions A better understanding of these mechanisms, will contribute to better disease management as treatment strategies can be chosen based on the specific disease properties, since a growing number of treatments are targeting DDR pathway alterations (such as Poly(ADP-ribose) polymerase inhibitors). Furthermore, the recently discovered crosstalk between the DDR and androgen receptor signaling opens a new array of possible strategies to optimize treatment combinations. We discuss how these recent and ongoing studies will help to improve diagnostic, prognostic and therapeutic approaches for PCa management.
- Published
- 2020